Researchers Find 30% Urine-Volume Cut via New Kidney Water Pathway Using Probenecid
Updated
Updated · The Economic Times · Jun 16
Researchers Find 30% Urine-Volume Cut via New Kidney Water Pathway Using Probenecid
3 articles · Updated · The Economic Times · Jun 16
Summary
A small clinical trial and preclinical studies found probenecid cut urine volume by about 30% while preserving tolvaptan’s benefit in polycystic kidney disease patients.
The finding emerged unexpectedly when researchers tested the 1940s drug in kidney cell models and saw it slow, rather than worsen, cyst growth.
Further work showed probenecid affects urate signaling, triggering water channels to move to kidney-cell surfaces and helping concentrate urine through a pathway distinct from vasopressin.
That mechanism could ease a major drawback of tolvaptan, the only approved PKD therapy, which often drives urine output to 6 to 7 liters a day and can push patients to stop treatment.
Researchers say probenecid itself is not the end goal because it acts broadly; they aim to build more targeted drugs around the newly identified water-control pathway.
With Congress now backing research, could this discovery fast-track a new generation of kidney disease drugs?
The key to helping kidneys also harms immunity. Can science safely target this newly found pathway?
Discovery of a Vasopressin-Independent Urate Pathway for Kidney Water Regulation: Probenecid’s Role and New Therapeutic Horizons for PKD
Overview
Researchers at the Mayo Clinic, led by Dr. Fouad Chebib, have discovered a new pathway for kidney water regulation that works independently of the hormone vasopressin. This breakthrough, published in the Journal of Clinical Investigation, was made possible by the unexpected effects of the drug probenecid during studies on polycystic kidney disease. While probenecid played a key role in revealing this mechanism, it affects many systems in the body and is no longer widely available, so it is not seen as a long-term treatment. The discovery opens new possibilities for developing targeted therapies for kidney disorders.